

HOSPITAL CLÍNIC RESEARCH ETHICS COMMITTEE REPORT

ANA LUCIA ARELLANO ANDRINO, as a secretary of the **Research Ethics Committee of the Hospital Clínic of Barcelona**

Certifies:

This Committee evaluated the sponsor's application to carry out the following project:

PROTOCOL NUMBER:

DOCUMENTS WITH VERSIONS:

Type	Version
Protocolo	v1.0 de 11/04/2020

PROTOCOL TITLE: Liver Cancer Outcome in the COVID19-pandemic. (CERO-19)

SPONSOR:

HOSPITAL CLÍNIC BARCELONA. DR. ALEJANDRO FORNER, DRA. MARIA REIG.
IRCCS CÀ GRANDA OSPEDALE MAGGIORE POLICLINICO. DR. MASSIMO LAVARONE

PRINCIPAL INVESTIGATOR: MARIA REIG ; ALEJANDRO FORNER GONZÁLEZ

and considers that, after having taken into account the responses to the request for clarifications (if any), and that:

- The protocol description complies with the study objectives and the potential risks and nuisances are justified.
- The ability of the investigator(s) and the facilities are suitable for carrying out the study.
- The compensation available to subjects (if present) and its hypothetical interference with ethical principles have been evaluated and found suitable.
- The proposed study meets ethical principles and our centre's deontological criteria.
- The proposed study is included in one of the clinical investigation lines accepted in our centre and is feasible.
- The proposed study complies with the principal requirements established by Spanish legislation on research and data protection.

Therefore this Research Ethics Committee accepts that the study be carried out and any change to the approved protocol and any serious adverse event should be notified.

And states that:

1º In the meeting of 16 April 2020, reference 7/2020, the approval report was announced.

2º The Research Ethics Committee of Hospital Clínic de Barcelona, in its composition and in its SOPs, meets Good Clinical Practice guidelines (CPMP/ICH/135/95)

3º The list of members:

Chair:

- JOAQUIM FORÉS I VIÑETA (Médico Traumatólogo, HCB)

Vice- Chair:

- ANDREA SCALISE (Médico Farmacólogo Clínico, HCB)

Secretary:

- ANA LUCIA ARELLANO ANDRINO (Médico Farmacólogo Clínico, HCB)

Members:

- ITZIAR DE LECUONA (Jurista, Observatorio de Bioética y Derecho, UB)
- MONTSERRAT GONZALEZ CREUS (Trabajadora Social, Servicio de Atención al Usuario, HCB)
- JOSE RIOS GUILLERMO (Estadístico. Plataforma de Estadística Médica. IDIBAPS)
- OCTAVI SANCHEZ LOPEZ (Representante de los pacientes)
- MARIA JESÚS BERTRAN LUENGO (Médico Epidemiólogo, HCB)
- JOAQUÍN SÁEZ PEÑATARO (Médico Farmacólogo Clínico, HCB)
- SERGI AMARO DELGADO (Médico Neurólogo, HCB)
- JULIO DELGADO GONZÁLEZ (Médico Hematólogo, HCB)
- EDUARD GUASCH CASANY (Médico Cardiólogo, HCB)
- VIRGINIA HERNANDEZ GEA (Médico Hepatólogo, HCB)
- MARINA ROVIRA ILLAMOLA (Farmacéutico Atención Primaria, CAP Eixample)
- MIRIAM MENDEZ GARCÍA (Abogada, HCB)
- JOSE TOMAS ORTIZ PEREZ (Médico Cardiólogo, HCB)
- BEGOÑA GOMEZ PEREZ (Farmacéutica Hospitalaria, HCB)
- ELENA CALVO CIDONCHA (Farmacéutica Hospitalaria, HCB)
- CECILIA CUZCO CABELLOS (Enfermera, HCB)

If a member is an investigator involved in some of the protocols evaluated, the member will leave the room during the discussion process.

Barcelona, 8 May 2020

Reg. HCB/2020/0454

Mod_04 (V3 29/06/2016)

PI_ENG